INmune Bio presents data on INB03’s role as immune check point

INmune Bio is presenting data on the use of INB03, a dominant-negative tumor necrosis factor TNF inhibitor of soluble TNF sTNF in the treatment of high-risk MUC4 expressing HER2+ and triple negative breast cancer TNBC . INB03 is shown to decrease T cell and macrophage immune checkpoint proteins PD1, TIGIT, LAG3, CD47 and SIRPa in a model immunotherapy resistant HER2+ breast cancer and decrease the metastatic potential of TNBC by downregulating cell surface markers of tumor invasion . The two posters will be presented at the annual American Association of Cancer Research in San Diego on April 8, 2024.”Dr. Schillaci has shown that MUC4 expression in high-risk breast cancer subtypes is a predictor of resistance to therapy due to an unfavorable immunobiology of the TME and increased metastatic potential that is driven by soluble TNF,” said RJ Tesi M.D., CEO of INmune Bio. “Neutralization of soluble TNF changes a resistant tumor biology into one that is more favorable. All of the individuals involved in this project share the belief that prospectively determining MUC4 expression in high-risk breast cancer subtypes will guide therapy decisions and significantly impact patient outcomes.”